Press Releases
La controllata Philochem AG ha concesso in licenza i diritti a livello mondiale su OncoACP3, un nuovo agente terapeutico e diagnostico per il trattamento del cancro alla prostata, a RayzeBio, società del gruppo Bristol-Myers Squibb, per un valore fino a 1,35 miliardi di dollari più royalties.
Read moreUpcoming Events
Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
Following last night’s announcement regarding OncoACP3, we are pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET. Please contact...
Read morePhilogen to attend AACR 2025 on April 25-30, 2025
Claudia Comacchio is presenting a poster about Philochem’s ACP3 antibody therapeutics on April 29, entitled “Generation and in vivo characterization of a novel antibody targeting Prostatic Acid Phosphatase (ACP-3)” ....
Read morePhilogen to attend the PEGS Boston 2025 on May 13-16, 2025
Dr. Sebastian Oehler will present Philochem’s recent discovery in the field of prostate cancer under the title “From DNA-Encoded Chemistry to ACP3-Targeted Radioligand Therapeutics against Prostate Cancer” on May 13th...
Read morePast Events
Philogen FY 2024 report on April 2, 2025
Philogen is pleased to invite you to an upcoming webinar on April 2, 2025, at 15:00 GMT | 16:00 CET.
Click on the link to register or contact us at IR@philogen.com
Philogen to attend the Swiss Radiopharmacy Day on March 21, 2025
Our certified radiation protection experts, Dr. Jacqueline Mock and Dr. Sebastian Oehler, will take part and represent Philochem in the Swiss Radiopharmacy Day.
Philogen to attend the ESMO-ImmunoOncology (ESMO-IO) Congress 2024 in Geneva (Switzerland) on December 13, 2024
Prof. Dario Neri gave a presentation on “Armed antibodies”